Comparison of Combined Bevacizumab plus Dexamethasone Vs . Ranibizumab Monotherapy as First-Line Therapy in Patients with Treatment Naive Neovascular Age-Related Macular Degeneration in Real-Life Clinical Practice: A Retrospective Case-Series Analysis
2017
Purpose: To identify the differences between combination bevacizumab plus dexamethasone and ranibizumab in
treatment naive neovascular age-related macular degeneration in terms of functional/morphological outcomes and
number of injections when evaluated in real-life clinical practice.
Methods: We compared two groups of patients either receiving intravitreal bevacizumab (1.25 mg) plus
dexamethasone sodium phosphate (0.2 mg) or intravitreal ranibizumab (0.5 mg) over a 12 month period. The
former, Group A, received treatment at baseline and followed a pro re nata (PRN) regimen. The latter, Group B,
received treatment at baseline followed by two additional monthly injections as per the universally accepted protocol
whilst continuing treatment on PRN regimen thereafter. Best-corrected visual acuity (BCVA), intraocular pressure
(IOP), slit-lamp fundus examination and central macular thickness (CMT) via optical coherence tomography (OCT)
were recorded at the initial visit (Baseline, BSL) and at each subsequent follow-up visit.
Results: CMT at BSL was 362.8 ± 45.4 μm in Group A and 358.3 ± 47.2 μm in Group B. At the end of the data
analysis, CMT was improved substantially in both groups (246.1 ± 42.4 μm in Group A, 254.9 ± 21.2 μm in Group
B), while BCVA improved as well (From 0.87 ± 0.15 logMAR to 0.48 ± 0.15 in Group A, from 0.81 ± 0.20 logMAR to
0.52 ± 0.10 in Group B). Group A received 248 injections, whereas Group B received 313.
Conclusion: Combination treatment with DSP and bevacizumab provided the same efficacy and allowed a
statistically significant reduction in the frequency of injections compared with ranibizumab monotherapy.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
55
References
1
Citations
NaN
KQI